Tag: Payer Perspectives

Biosimilars Are Coming, Biosimilars Are Coming!

Biosimilars are knocking at our doors, and they certainly have a lot to say. Biosimilar products are biological products that are approved based on showing that they are highly similar to FDA-approved biological products, known as reference products, showing no clinically meaningful differences in terms of safety and effectiveness.

Read more
The Population Situation – The Future of Payer Perspectives

Some large payers with sophisticated infrastructure can answer their own questions – by analyzing their own data and assessing their broad “population situation” within and across multiple disease states. We have seen the big dogs start in areas known as the “low hanging fruit” – diabetes, CHF, COPD, etc., which are also areas where existing quality measures and/or incentives/disincentives are applied.

Read more